SAN CARLOS, Calif.-- October 14, 2026 -- Altay Therapeutics, Inc., a biotechnology company developing novel small molecule inhibitors of transcription factors, today announced the completion of a $37 million Series...
Canada-U.S. syndicate back Milestone Pharma's oral drug for cardiac arrhythmia
News | 06. 20. 2011
Milestone Pharmaceuticals
Making the Milestone
The venture arm of the Business Development Bank of Canada helped lead a C$13 million ($13.3 million) series A round last week in cardiovascular play Milestone Pharmaceuticals Inc. The financing is intended to help develop an oral candidate to treat a form of cardiac arrhythmia.
